From May 15-17 at booth 28, where we will be showcasing our Parsortix® technology and new Portrait®+ CTC staining kit*.

A new agreement with a major global pharmaceutical company to develop a Parsortix® CTC based Androgen Receptor (AR) assay for use in prostate cancer studies.

Visit our booth to learn how we offer a bespoke service with molecular and imaging CTC assays customised to your requirements.

Working in partnership with a major global biopharmaceutical provider, we will be tailoring our existing Parsortix-based DNA damage response (DDR) assay for use in pharmaceutical R&D.

On booth 3054 where we’ll be showcasing our Parsortix® technology and new Portrait®+ CTC staining kits at the San Diego Convention Centre.

Precision Medicine Poster Session at EBCC where we have two posters on display at poster board PB-117 & PB-123.

We are excited to share that our first lot of Portrait+ CTC Staining Kits are packed and ready to go out to our customers.

Anne-Sophie Pailhes-Jimenez, Senior Director, Head of R&D talks at 10:00-10:30 discussing PD-L1 expression in cancer cells from metastatic cancer patients.

Connect with us to learn about the power of Parsortix® technology and our clinical laboratory and to discover how we can support your clinical studies.

It is great to have so many of our friends and colleagues together to strengthen inter-department relationships.